Tuberculosis following PD-1 blockade for cancer immunotherapy

Science Translational Medicine

Volumn 11, Issue 475, 2019, Pages

  Barber, Daniel L ^a   Sakai, Shunsuke ^a   Kudchadkar, Ragini R ^b   Fling, Steven P ^c   Day, Tracey A ^d   Vergara, Julie A ^d   Ashkin, David ^e   Cheng, Jonathan H ^f   Lundgren, Lisa M ^c   Raabe, Vanessa N ^g   Kraft, Colleen S ^h   Nieva, Jorge J ^f   Cheever, Martin A ^c   Nghiem, Paul T ⁱ   Sharon, Elad ^j  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g EMORY UNIVERSITY   (United States)

^h EMORY UNIVERSITY HOSPITAL   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; LINEZOLID; LIVER ENZYME; MOXIFLOXACIN; NIVOLUMAB; OXYGEN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BODY WEIGHT LOSS; BRONCHOSCOPY; CANCER IMMUNOTHERAPY; CASE REPORT; CAUCASIAN; CHILL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; COUGHING; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEVER; HUMAN; HUMAN TISSUE; HYPOTENSION; LUNG LAVAGE; LUNG TUBERCULOSIS; MALE; MERKEL CELL CARCINOMA; MIDDLE AGED; MIGRATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NIGHT SWEAT; OXYGEN THERAPY; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; VERY ELDERLY; VIDEO ASSISTED THORACOSCOPIC SURGERY; VIET NAM; ADVERSE EVENT; ANIMAL; FATALITY; GRANULOMA; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; NASOPHARYNX TUMOR; NEOPLASM; PATHOLOGY; TH1 CELL; TUBERCULOSIS;

AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, MERKEL CELL; FATAL OUTCOME; GRANULOMA; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASMS; NIVOLUMAB; PROGRAMMED CELL DEATH 1 RECEPTOR; TH1 CELLS; TUBERCULOSIS;

EID: 85060156769     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aat2702     Document Type: Article

References (33)

1. M. N. Wykes, S. R. Lewin, Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol. 18, 91-104 (2018).
2. D. L. Barber, E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, R. Ahmed, Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
3. A. Zumla, M. Rao, E. Dodoo, M. Maeurer, Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med. 14, 89 (2016).
4. R. S. Wallis, R. Hafner, Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 15, 255-263 (2015).
5. + T-cells. PLOS ONE 11, e0158262 (2016).
6. C. L. Day, D. A. Abrahams, R. Bunjun, L. Stone, M. de Kock, G. Walzl, R. J. Wilkinson, W. A. Burgers, W. A. Hanekom, PD-1 expression on Mycobacterium tuberculosis-specific CD4 T cells is associated with bacterial load in human tuberculosis. Front. Immunol. 9, 1995 (2018).
7. M. Rao, D. Valentini, E. Dodoo, A. Zumla, M. Maeurer, Anti-PD-1/PD-L1 therapy for infectious diseases: Learning from the cancer paradigm. Int. J. Infect. Dis. 56, 221-228 (2017).
8. E. Lázár-Molnár, B. Chen, K. A. Sweeney, E. J. Wang, W. Liu, J. Lin, S. A. Porcelli, S. C. Almo, S. G. Nathenson, W. R. Jacobs Jr., Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 107, 13402-13407 (2010).
9. D. L. Barber, K. D. Mayer-Barber, C. G. Feng, A. H. Sharpe, A. Sher, CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J. Immunol. 186, 1598-1607 (2011).
10. S. Tousif, Y. Singh, D. V. R. Prasad, P. Sharma, L. Van Kaer, G. Das, T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLOS ONE 6, e19864 (2011).
11. S. Sakai, K. D. Kauffman, M. A. Sallin, A. H. Sharpe, H. A. Young, V. V. Ganusov, D. L. Barber, CD4 T cell-derived IFN- plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLOS Pathog. 12, e1005667 (2016).
12. J. J. X. Lee, A. Chan, T. Tang, Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. Acta Oncol. 55, 519-520 (2016).
13. K. Fujita, T. Terashima, T. Mio, Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J. Thorac. Oncol. 11, 2238-2240 (2016).
14. Y. C. Chu, K. C. Fang, H. C. Chen, Y. C. Yeh, C. E. Tseng, T. Y. Chou, C. L. Lai, Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma. J. Thorac. Oncol. 12, e111-e114 (2017).
15. H. Picchi, C. Mateus, C. Chouaid, B. Besse, A. Marabelle, J. M. Michot, S. Champiat, A. L. Voisin, O. Lambotte, Infectious complications associated with the use of immune checkpoint inhibitors in oncology: Reactivation of tuberculosis after anti PD-1 treatment. Clin. Microbiol. Infect. 24, 216-218 (2018).
16. S. Takata, G. Koh, Y. Han, H. Yoshida, T. Shiroyama, H. Takada, K. Masuhiro, S. Nasu, S. Morita, A. Tanaka, S. Hashimoto, K. Uriu, H. Suzuki, Y. Tamura, N. Okamoto, T. Nagai, T. Hirashima, Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents. J. Infect. Chemother. 25, 54-58 (2018).
17. B. B. Y. Ma, W.-T. Lim, B.-C. Goh, E. P. Hui, K.-W. Lo, A. Pettinger, N. R. Foster, J. W. Riess, M. Agulnik, A. Y. C. Chang, A. Chopra, J. A. Kish, C. H. Chung, D. R. Adkins, K. J. Cullen, B. J. Gitlitz, D. W. Lim, K.-F. To, K. C. A. Chan, Y. M. D. Lo, A. D. King, C. Erlichman, J. Yin, B. A. Costello, A. T. C. Chan, Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J. Clin. Oncol. 36, 1412-1418 (2018).
18. P. T. Nghiem, S. Bhatia, E. J. Lipson, R. R. Kudchadkar, N. J. Miller, L. Annamalai, S. Berry, E. K. Chartash, A. Daud, S. P. Fling, P. A. Friedlander, H. M. Kluger, H. E. Kohrt, L. Lundgren, K. Margolin, A. Mitchell, T. Olencki, D. M. Pardoll, S. A. Reddy, E. M. Shantha, W. H. Sharfman, E. Sharon, L. R. Shemanski, M. M. Shinohara, J. C. Sunshine, J. M. Taube, J. A. Thompson, S. M. Townson, J. H. Yearley, S. L. Topalian, M. A. Cheever, PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374, 2542-2552 (2016).
19. A. Cruz, A. G. Fraga, J. J. Fountain, J. Rangel-Moreno, E. Torrado, M. Saraiva, D. R. Pereira, T. D. Randall, J. Pedrosa, A. M. Cooper, A. G. Castro, Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J. Exp. Med. 207, 1609-1616 (2010).
20. A. Ribas, J. D. Wolchok, Cancer immunotherapy using checkpoint blockade. Science 359, 1350-1355 (2018).
21. S. Shafiani, C. Dinh, J. M. Ertelt, A. O. Moguche, I. Siddiqui, K. S. Smigiel, P. Sharma, D. J. Campbell, S. S. Way, K. B. Urdahl, Pathogen-specific Treg cells expand early during Mycobacterium tuberculosis infection but are later eliminated in response to interleukin-12. Immunity 38, 1261-1270 (2013).
22. S. Sakai, K. D. Kauffman, J. M. Schenkel, C. C. McBerry, K. D. Mayer-Barber, D. Masopust, D. L. Barber, Cutting edge: Control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J. Immunol. 192, 2965-2969 (2014).
23. K. D. Kauffman, M. A. Sallin, S. Sakai, O. Kamenyeva, J. Kabat, D. Weiner, M. Sutphin, D. Schimel, L. Via, C. E. Barry III, T. Wilder-Kofie, I. Moore, R. Moore, D. L. Barber, Defective positioning in granulomas but not lung-homing limits CD4 T-cell interactions with Mycobacterium tuberculosis-infected macrophages in rhesus macaques. Mucosal Immunol. 11, 462-473 (2018).
24. H. Li, B. Javid, Antibodies and tuberculosis: Finally coming of age? Nat. Rev. Immunol. 18, 591-596 (2018).
25. S. Gagneux, P. M. Small, Global phylogeography of mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis. 7, 328-337 (2007).
26. W. W. Reiley, S. Shafiani, S. T. Wittmer, G. Tucker-Heard, J. J. Moon, M. K. Jenkins, K. B. Urdahl, G. M. Winslow, D. L. Woodland, Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. U.S.A. 107, 19408-19413 (2010).
27. T. Einarsdottir, E. Lockhart, J. L. Flynn, Cytotoxicity and secretion of gamma interferon are carried out by distinct CD8 T cells during Mycobacterium tuberculosis infection. Infect. Immun. 77, 4621-4630 (2009).
28. World Health Organization, “Global Tuberculosis Report 2017” (Geneva, Switzerland, 2017).
29. S. Sakai, I. Kawamura, T. Okazaki, K. Tsuchiya, R. Uchiyama, M. Mitsuyama, PD-1-PD-L1 pathway impairs Th1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guérin. Int. Immunol. 22, 915-925 (2010).
30. P. Jayaraman, M. K. Jacques, C. Zhu, K. M. Steblenko, B. L. Stowell, A. Madi, A. C. Anderson, V. K. Kuchroo, S. M. Behar, TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection. PLOS Pathog. 12, e1005490 (2016).
31. G. C. Ireton, R. Greenwald, H. Liang, J. Esfandiari, K. P. Lyashchenko, S. G. Reed, Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value. Clin. Vaccine Immunol. 17, 1539-1547 (2010).
32. National TB Controllers Association/Center for Disease Control and Prevention Advisory Group on Tubercolosis Genotyping, “Guide to the application of genotyping to tuberculosis prevention and control,” (U.S. Department of Health and Human Service, Atlanta, GA, 2004).
33. S. Ghosh, P. K. Moonan, L. Cowan, J. Grant, S. Kammerer, T. R. Navin, Tuberculosis genotyping information management system: Enhancing tuberculosis surveillance in the United States. Infect. Genet. Evol. 12, 782-788 (2012).